Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

by McAuley, Daniel F , Minassian, Angela M , Pretswell, Carol H , Boffito, Marta , Goodman, Anna L , Albert, Gary , Jamal, Arham , Packham, Jonathan , Browne, Duncan , Munsoor, Imrozia , Smith, Kathy , Burns, Fiona , Sheridan, Ray P , Iyengar, Shalini , Heath, Paul T , Toback, Seth , Soiza, Roy L , Jeanes, Christopher , Moore, Patrick , Cho, Iksung , Rivers, Joy , Cosgrove, Catherine , Chadwick, David R , Smith, Richard , Kalra, Philip A , Kyriakidou, Christina , Galloway, James , Clark, Rebecca , Nicholls, Helen , Osanlou, Orod , Thomson, Emma C , Meyrick, Agnieszka , Saralaya, Dinesh , Robertson, Andreana , Dubovsky, Filip , Galiza, Eva P , San Francisco Ramos, Alberto , Glenn, Greg , Higham, Andrew , Swift, Pauline A , Turner, Jeremy , Heer, Amardeep , Minton, Jane , Baxter, David N , Viljoen, Marianne E

in Adolescent / Adult / Adverse events / Aged / Aged, 80 and over / Coronavirus / Coronaviruses / COVID-19 / COVID-19 - epidemiology / COVID-19 - prevention & control / COVID-19 vaccines / COVID-19 Vaccines - administration & dosage / COVID-19 Vaccines - adverse effects / COVID-19 Vaccines - immunology / Disease transmission / Humans / Hypotheses / Immune response / Immunogenicity / Immunogenicity, Vaccine / Infections / Infectious Disease / Influenza / Injection / Injections, Intramuscular - adverse effects / Middle Aged / Nanoparticles / Original / Pandemics / Placebos / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Single-Blind Method / Spike glycoprotein / Statistical analysis / Vaccine efficacy / Vaccines / Vaccines, Synthetic - immunology / Young Adult

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

2021

Confirm

Do you wish to request the book?

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

McAuley, Daniel F,

Minassian, Angela M,

Pretswell, Carol H,

Boffito, Marta,

Goodman, Anna L,

Albert, Gary,

Jamal, Arham,

Packham, Jonathan,

Browne, Duncan,

Munsoor, Imrozia,

Smith, Kathy,

Burns, Fiona,

Sheridan, Ray P,

Iyengar, Shalini,

Heath, Paul T,

Toback, Seth,

Soiza, Roy L,

Jeanes, Christopher,

Moore, Patrick,

Cho, Iksung,

Rivers, Joy,

Cosgrove, Catherine,

Chadwick, David R,

Smith, Richard,

Kalra, Philip A,

Kyriakidou, Christina,

Galloway, James,

Clark, Rebecca,

Nicholls, Helen,

Osanlou, Orod,

Thomson, Emma C,

Meyrick, Agnieszka,

Saralaya, Dinesh,

Robertson, Andreana,

Dubovsky, Filip,

Galiza, Eva P,

San Francisco Ramos, Alberto,

Glenn, Greg,

Higham, Andrew,

Swift, Pauline A,

Turner, Jeremy,

Heer, Amardeep,

Minton, Jane,

Baxter, David N,

Viljoen, Marianne E

2021

Overview

In a phase 3 trial involving more than 15,000 participants, two doses of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, administered 21 days apart had a vaccine efficacy of 89.7%. Reactogenicity was generally mild and transient, and adverse events were infrequent and of low grade.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Adult

/ Aged